Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CASI Pharmaceuticals, Inc.

https://www.casipharmaceuticals.com/

Latest From CASI Pharmaceuticals, Inc.

FTC’s Take On Two Pharma Mergers Shows Deals Can Clear Higher Hurdle

Pfizer’s acquisition of Arena without FTC intervention and Hikma’s acquisition of Custopharm with one product divestiture shows the commission is bound by anticompetitive facts of a deal. A more controversial merger may not get through, former FTC attorney says.

M & A Commercial

Babyganics Recalls Selected Bubble Baths Due To Potential Contamination

The SC Johnson brand is providing full refunds to consumers who purchased the chamomile verbena Bubble Bath products, which may contain a bacterium that is potentially harmful to the immunocompromised and those with broken or irritated skin, “such as diaper rash.”

Cosmetics Recalls

Asia Deal Watch: Juniper Licenses Asia-Pacific-Plus Rights To Kolon’s Osteoarthritis Cell Therapy

Plus deals involving Shionogi/NEC, Ji Xing/LENZ, Kyowa Kirin/Ardelyx, CR Pharma/Everest Medicine and Dr Reddy’s/Novartis.

Deal Watch Business Strategies

FDA Guidance On Transitioning COVID-19 EUA Products Has US Firms Watching The Clock

Stakeholders across medtech industry submit comments on FDA's itsplans to help companies looking to keep their EUA products on the market post-pandemic.

Coronavirus COVID-19 Guidance Documents
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Other Names / Subsidiaries
    • EntreMed, Inc.
    • Miikana Therapeutics, Inc.
UsernamePublicRestriction

Register